Navigation Links
Supelco(R) and MIP Technologies Launch New SPE Product for the Selective Extraction of NSAIDs From Environmental Water
Date:7/16/2009

ST. LOUIS, July 16 /PRNewswire-FirstCall/ -- Supelco, a division of Sigma-Aldrich (Nasdaq: SIAL), and MIP Technologies AB announced today the launch of a new molecularly imprinted polymer, SPE product, SupelMIP(TM), for the selective extraction of non-steroidal anti-inflammatory drugs (NSAIDs).

"SupelMIP NSAIDS is an important addition to our portfolio because it targets a critical area of public concern - the increasing appearance of prescription and over-the-counter drugs in environmental water," said Anthony Rees, CEO of MIP Technologies. "This concern is reflected in the programs initiated by many governments to monitor national water resources for the presence and concentrations of the most frequently used drugs having the potential for adverse effects. This product recognizes members of the class of NSAIDs related to ibuprofen and will simplify the analysis of these drugs when present, at even low levels, in natural water samples."

SupelMIP was developed for confirmation and quantitation of NSAID drugs in water samples. The SPE phase has been developed for multi-residue extraction of NSAIDs and has been validated for ibuprofen, diclofenac, naproxen, clofibric acid, celecoxob and piroxicam.

"SupelMIP SPE allows researchers to selectively extract and recover non-steroidal anti-inflammatory drugs," said An Trinh, product manager of Sample Prep at Supelco. "Such compounds are among the most highly consumed pharmaceuticals in the world."

Ibuprofen, diclofenac and naproxen are non-steroidal anti-inflammatory drugs that have analgesic and antipyretic activities. Clofibric acid is an active metabolite of clofibrate, etofibrate and etofyllinclofibrate. These compounds are used as blood lipid regulators. Because of the pharmacological activity of the NSAIDs and the possibility of entry into the domestic water cycle, the concentrations need to be accurately quantified in natural water samples.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has 7,800 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.

About MIP Technologies: MIP Technologies AB is a world-leading company in the development of molecularly imprinted polymers (MIPs) and other novel polymers. The Company is a pioneer in the commercial applications of MIPs, holds important patents and maintains cutting-edge research activities in this area. The Company's mission is to provide innovative products based on molecularly imprinted polymers that serve industry's needs in analytical, preparative and process scale 'selective separations'. The Company has the ability to produce MIPs and other selective polymers from laboratory to pilot scale and is well placed to develop large-scale separation solutions for its customers. Currently, the Company develops analytical separation products (e.g. SPE) and has multiple custom process scale projects in place with several blue chip companies. MIP Technologies has its headquarters in Lund, Sweden. For more information about MIP Technologies AB visit www.miptechnologies.com

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Companies' expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Companies' operations and conditions in the markets the Companies serve. The Companies do not undertake any obligation to update these forward-looking statements.

Sigma-Aldrich and Supelco are registered trademarks of Sigma-Aldrich Biotechnology LP and Sigma-Aldrich Co. Supel-MIP is a trademark of Supelco.


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Supelco(R) Expands Ascentis(R) Express HPLC Columns Line for High-Speed and High-Efficiency Separations
2. Supelco(R) Introduces Ascentis(R) Express HILIC HPLC Columns for High-Speed and High-Efficiency Separations
3. ImmunoVaccine Technologies Licenses Immunotopes Breast, Ovarian and Prostate Cancer Antigens
4. Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing
5. Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia
6. IDEV Technologies Names Veteran Medical Device Executive Rick Anderson Chairman of the Board of Directors
7. BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes
8. BioStorage Technologies, Inc., Appoints Jeff Goddard to Global Head of Sales
9. Greenway Medical Technologies To Display Live Interoperability Implementations at 2009 DIA Show
10. BioEnergy International, LLC Announces Formation of Myriant Technologies LLC
11. Wound Management Technologies, Inc. Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... ... a new agreement with Singapore-based Global Stem Cells Network (GSCN) and its affiliate ... and Singapore in the latest adipose and bone marrow therapies. , Through ...
(Date:2/9/2016)... ... , ... Date and time: March 1, 2016, 5:30 p.m. ... Center of Bucks County, 3805 Old Easton Road, Doylestown, PA 18902. , The ... open house for participants to learn about a new Master of Biomedical Science ...
(Date:2/9/2016)... CA (PRWEB) , ... February 09, 2016 , ... ... strategic changes over the years and Open Access publishing is one of the ... With its 700+ open access journals and 3000+ International Conferences ...
(Date:2/9/2016)... Three-Year Initiative Supports Next Generation of ... in Life-Changing Camp Experiences ... affect the lives of children born with rare diseases, as well ... ) is announcing a new initiative designed to positively affect the ... future of rare disease care. --> To mark the ...
Breaking Biology Technology:
(Date:2/9/2016)... 2016 Vigilant Solutions announces today that an agency ... develop a lead in a difficult homicide case. The agency ... locate the suspect vehicle. Due to the ongoing investigation, the ... omitted at the agency,s request. --> ... victim was found deceased at an intersection here in the ...
(Date:2/3/2016)... , February 3, 2016 ... market research report "Automated Fingerprint Identification System Market by ... Search), Application (Banking & Finance, Government, Healthcare, and Transportation) ... MarketsandMarkets, the market is expected to be worth USD ... 21.0% between 2015 and 2020. The transformation and technology ...
(Date:2/2/2016)... Feb. 2, 2016 Checkpoint Inhibitors for ... Market Are you interested in the future ... for checkpoint inhibitors. Visiongain,s report gives those predictions ... and national level. Avoid falling behind in ... opportunities and revenues those emerging cancer therapies can ...
Breaking Biology News(10 mins):